Maverick Capital Ltd. Has $73.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Maverick Capital Ltd. raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 14,351.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 4,377,690 shares of the company’s stock after buying an additional 4,347,398 shares during the quarter. Teva Pharmaceutical Industries comprises about 1.1% of Maverick Capital Ltd.’s portfolio, making the stock its 27th largest holding. Maverick Capital Ltd.’s holdings in Teva Pharmaceutical Industries were worth $73,370,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $41,000. Sound Income Strategies LLC boosted its holdings in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares during the last quarter. MAI Capital Management grew its position in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares in the last quarter. Brooklyn Investment Group increased its stake in Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after buying an additional 4,014 shares during the last quarter. Finally, CWM LLC lifted its position in Teva Pharmaceutical Industries by 18.1% during the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after buying an additional 767 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares in the company, valued at $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 532,360 shares of company stock worth $14,364,929. Company insiders own 0.49% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Bank of America raised their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday. UBS Group increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday. Scotiabank began coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Finally, Barclays initiated coverage on Teva Pharmaceutical Industries in a report on Tuesday. They issued an “overweight” rating and a $35.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average price target of $30.25.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $30.16 on Friday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $30.20. The stock has a market cap of $34.59 billion, a price-to-earnings ratio of 50.27, a PEG ratio of 1.77 and a beta of 0.67. The business has a 50 day moving average of $23.23 and a 200-day moving average of $19.51. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.